CGH 2466 dihydrochlorideadenosine receptor antagonist CAS# 1177618-54-0 |
2D Structure
- Biperiden HCl
Catalog No.:BCC4565
CAS No.:1235-82-1
- Darifenacin
Catalog No.:BCC1516
CAS No.:133099-04-4
- Darifenacin HBr
Catalog No.:BCC4567
CAS No.:133099-07-7
- Cevimeline hydrochloride hemihydrate
Catalog No.:BCC1471
CAS No.:153504-70-2
- Umeclidinium bromide
Catalog No.:BCC2022
CAS No.:869113-09-7
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 1177618-54-0 | SDF | Download SDF |
PubChem ID | 16759176 | Appearance | Powder |
Formula | C14H11Cl4N3S | M.Wt | 395.13 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 10 mM in DMSO with gentle warming and to 5 mM in ethanol | ||
Chemical Name | 4-(3,4-dichlorophenyl)-5-pyridin-4-yl-1,3-thiazol-2-amine;dihydrochloride | ||
SMILES | C1=CC(=C(C=C1C2=C(SC(=N2)N)C3=CC=NC=C3)Cl)Cl.Cl.Cl | ||
Standard InChIKey | WHXRCTIBFLXKFD-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C14H9Cl2N3S.2ClH/c15-10-2-1-9(7-11(10)16)12-13(20-14(17)19-12)8-3-5-18-6-4-8;;/h1-7H,(H2,17,19);2*1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Adenosine A1, A2B and A3 receptor antagonist (IC50 values are 19, 21, and 80 nM respectively). Also inhibits p38 MAPK (IC50 = 187 - 400 nM) and phosphodiesterase type 4D (IC50 = 22 nM). Displays potent anti-inflammatory effects in vitro and in vivo. Potentially useful for asthma and chronic obstructive pulmonary disease (COPD) research. |
CGH 2466 dihydrochloride Dilution Calculator
CGH 2466 dihydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.5308 mL | 12.6541 mL | 25.3081 mL | 50.6163 mL | 63.2703 mL |
5 mM | 0.5062 mL | 2.5308 mL | 5.0616 mL | 10.1233 mL | 12.6541 mL |
10 mM | 0.2531 mL | 1.2654 mL | 2.5308 mL | 5.0616 mL | 6.327 mL |
50 mM | 0.0506 mL | 0.2531 mL | 0.5062 mL | 1.0123 mL | 1.2654 mL |
100 mM | 0.0253 mL | 0.1265 mL | 0.2531 mL | 0.5062 mL | 0.6327 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
CGH 2466 dihydrochloride is a combined adenosine receptor antagonist. It is an inhibitor of phosphodiesterase type 4 and p38 mitogen-activated protein kinase. It inhibited the phosphodiesterase 4D (PDE4D) isoenzyme with an IC50 value of 22±5 nM. It inhibited the p38 mitogen-activated protein (MAP) kinases α and β with IC50 values of 187±18, 400±38 nM, respectively [1].
There are four adenosine receptor subtypes of the G protein-coupled receptor family, designated as A1, A2A, A2B and A3 [2]. Adenosine plays a role in the control of inflammation [3]. Phosphodiesterases can inactivate cAMP. In inflammatory cells, phosphodiesterase-4 (PDE4) is the predominant isoenzyme [4]. In mammalian cells, the p38 MAPK was thought to be important for regulating cellular responses during infection via its effects on the expression of proinflammatory molecules [5].
CGS15943 is a broad spectrum adenosine antagonist, SB203580 is a prototypical inhibitor of the p38 MAP kinase, and cilomilast is a standard inhibitor of PDE4. Data showed that CGH2466 was similar to SB203580 in potency as a p38 MAP kinase inhibitor, and was similar to cilomilast in activity to inhibit PDE4D. Compared to CGS15943, CGH 2466 showed similar potency to inhibit A1, A2B and A3 adenosine receptors. In contrast to CGS15943, CGH2466 was not active at the A2A receptor. Compared with other above compounds, CGH2466 was an inhibitor of the highest potency to inhibit selected enzymes or receptors in leucocyte-based assays [1].
48 h after the allergen challenge, bronchoalveolar lavage recovered eosinophil numbers. In sensitized mice, aerosol challenge of ovalbumin was able to increase these eosinophil numbers. In this animal model of asthmatic inflammation, 15 min before and 24 h after the challenge, the intranasal administration of CGH2466, dose-dependently inhibited the airway eosinophilia induced by ovalbumin, reaching significant levels at doses of 3 and 10 mg.kg-1 [1].
References:
[1]. Trifilieff A, Keller TH, Press NJ, et al. CGH2466, a combined adenosine receptor antagonist, p38 mitogen‐activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti‐inflammatory activities. British journal of pharmacology, 2005, 144(7): 1002-1010.
[2]. Klotz KN, Hessling J, Hegler J, et al. Comparative pharmacology of human adenosine receptor subtypes-characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg's archives of pharmacology, 1997, 357(1): 1-9.
[3]. Yang D, Zhang Y, Nguyen HG, et al. The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. The Journal of clinical investigation, 2006, 116(7): 1913-1923.
[4]. Gamble E, Grootendorst DC, Brightling CE, et al. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 2003, 168(8): 976-982.
[5]. Han J, Jiang Y, Li Z, et al. Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. 1997, 386(6622):296-299.
- SMANT hydrochloride
Catalog No.:BCC6254
CAS No.:1177600-74-6
- N20C hydrochloride
Catalog No.:BCC7292
CAS No.:1177583-87-7
- Forsythoside I
Catalog No.:BCN6430
CAS No.:1177581-50-8
- Felbamate hydrate
Catalog No.:BCC4160
CAS No.:1177501-39-1
- (R)-(+)-Blebbistatin
Catalog No.:BCC7195
CAS No.:1177356-70-5
- CKI 7 dihydrochloride
Catalog No.:BCC5614
CAS No.:1177141-67-1
- Doramectin
Catalog No.:BCC1536
CAS No.:117704-25-3
- Dexamethasone acetate
Catalog No.:BCC4775
CAS No.:1177-87-3
- Laxogenin
Catalog No.:BCN8434
CAS No.:1177-71-5
- DL-Syringaresinol
Catalog No.:BCN6053
CAS No.:1177-14-6
- LY 255283
Catalog No.:BCC7290
CAS No.:117690-79-6
- Agomelatine hydrochloride
Catalog No.:BCC4210
CAS No.:1176316-99-6
- Azithromycin Dihydrate
Catalog No.:BCC4631
CAS No.:117772-70-0
- Decumbenine C
Catalog No.:BCC8314
CAS No.:117772-89-1
- Desmethyl-YM 298198
Catalog No.:BCC7365
CAS No.:1177767-57-5
- AP-III-a4
Catalog No.:BCC5292
CAS No.:1177827-73-4
- NSC 23766
Catalog No.:BCC1149
CAS No.:1177865-17-6
- 3,3',4',5,6,7,8-heptamethoxyflavone
Catalog No.:BCN8203
CAS No.:1178-24-1
- Enterostatin
Catalog No.:BCC6050
CAS No.:117830-79-2
- Ac-Asp(OtBu)-OH
Catalog No.:BCC2880
CAS No.:117833-18-8
- Loreclezole hydrochloride
Catalog No.:BCC7009
CAS No.:117857-45-1
- L-CCG-l
Catalog No.:BCC6609
CAS No.:117857-93-9
- L-CCG-lll
Catalog No.:BCC6608
CAS No.:117857-95-1
- Fmoc-Thr(Bzl)-OH
Catalog No.:BCC3550
CAS No.:117872-75-0
CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activities.[Pubmed:15685201]
Br J Pharmacol. 2005 Apr;144(7):1002-10.
Theophylline, a phosphodiesterase inhibitor and adenosine receptor antagonist, is used in asthma and chronic obstructive pulmonary disease (COPD) treatment. However, the relatively low effectiveness of theophylline have recently led to reduced usage. The goal of the present study was to identify a theophylline-like compound with improved effectiveness. We discovered CGH2466, which not only antagonised the adenosine A1, A2b and A3 receptors with IC50 values of 19 +/- 4, 21 +/- 3 and 80 +/- 14 nM, respectively, but also inhibited the p38 mitogen-activated protein (MAP) kinases alpha and beta and the phosphodiesterase 4D (PDE4D) isoenzyme with IC50 values of 187 +/- 18, 400 +/- 38 and 22 +/- 5 nM, respectively. Despite similar potencies on individual targets, CGH2466 inhibited the production of cytokines and oxygen radicals by human peripheral blood leucocytes in vitro, more potently (IC50 values between 30 and 50 nM) than the standard p38 MAP kinase inhibitor SB203580 (30 nM to >1 microM), the PDE4 inhibitor cilomilast (120-400 nM) and the broad spectrum adenosine receptor antagonist CGS15943 (>10 microM). When given either orally or locally into the lungs, CGH2466 (3 to 10 mg kg(-1)) inhibited the ovalbumin- or lipopolysaccharide-induced airway inflammation in mice more potently than the single receptor antagonists or enzyme inhibitors used alone. In conclusion, CGH2466 through its combined activities at multiple targets exerted a powerful anti-inflammatory effect and therefore may have beneficial therapeutic value in diseases such as asthma and COPD.